NRAS and melanoma: This either means that the same rules do not apply in melanoma, that oncogenic KRAS and NRAS differ or that the mechanism of action of karonudib extends outside MTH1 inhibition, e.g., the proposed microtubule disruption caused by inhibitors of the same class as karonudib5–7.